FDA Accepts Vertex’s (VRTX) BLA for Povetacicept, Sets November 2026 PDUFA Date

Vertex Pharmaceuticals Inc. (VRTX) announced Monday the U.S. Food and Drug Administration accepted its biologics license application for povetacicept, an investigational treatment for IgA nephropathy, a progressive kidney disease. The FDA set a Prescription Drug User Fee Act target decision date in November 2026. The dual inhibitor of BAFF and APRIL aims to reduce proteinuria and slow kidney function decline. If approved, it would enter a market with limited disease-specific therapies and bolster Vertex’s pipeline beyond cystic fibrosis. The company estimates about 150,000 people in the U.S. have IgA nephropathy. Vertex shares are up 12% year-to-date. The company said a potential launch could generate meaningful revenue starting in 2027, though no sales forecasts were provided.